Published in Medical Letter on the CDC and FDA, May 16th, 2004
According to recent research from the U.K., "The 19-kDa C-terminal fragment of the malaria parasite merozoite surface protein 1 (MSP119 ) is a leading malaria vaccine candidate. In rodents, high antibody levels to this protein confer protective immunity, and can be generated by immunization with the antigen in adjuvants. In natural human infections, however, MSP119 -specific antibody responses can be short-lived and comparatively low, despite repeated exposure to infection.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.